Global health expert in vaccines, diagnostics and infectious disease prevention, advises SMi applying its technology to vaccine development and diagnostic testing.

CAMBRIDGE, UK — SMi Systems is delighted to introduce Dr Ankur Mutreja, Senior Advisor. Dr Mutreja is Director of Strategy, Partnerships and Communications at PATH for South Asia, where his leadership ensures the organisation and its partners implement strategic programs with the highest health security impact. Dr Mutreja also sits on the board of BactiVac, a catalytic bacterial vaccine network which funds bacterial vaccine R&D and academia-industry collaborations.

Previously he was the head of Global South Partnerships at CEPI (Coalition for Epidemic Preparedness Innovations) where he was responsible for managing strategic partnerships in vaccine development, equity and access. Dr Mutreja has extensive experience in industry and academia, including leading projects at the University of Cambridge, Novartis and MSD-Wellcome Hilleman Labs, and his published work on the spread of infectious disease has been widely cited. He holds honorary Professorial positions at institutes in India and the UK and has advised the World Health Organisation and the United Nations.

Dr Andrew Thompson, CEO at SMi says: “Ankur has led strategic focus on vaccines, diagnostics and epidemic preparedness initiatives throughout his impressive career, and we are thrilled that he is advising us on the future applications of SMi’s technology in these areas of need. Ankur’s experience will help to guide the application of SMi’s technology in vaccine development and routine population testing, both areas addressed by SMi’s early commercial products. His global view of pandemic preparedness and vaccine development will ensure the widest possible impact on human health, and his contacts will enable SMi’s technology to reach a wider customer base.”

Dr Mutreja commented: “I am continuously seeking technologies that can transform global health. At SMi, the team has greatly simplified experimental workflows through automation, multiplexing, and high-throughput capabilities that now enable direct observation of individual molecules within a sample. As SMi’s technology evolves, I see immense potential to accelerate vaccine development and scale up routine diagnostic testing for chronic diseases and for epidemic/pandemic preparedness. I’m thrilled to help guide SMi’s development towards initiatives with the greatest impact, recognising that both scientific innovation and commercial strategy are crucial for widespread technology deployment.”

For more information on SMi’s new platform and its single molecule imaging technology, please visit https://smisystems.co.uk/.

About SMi:

SMi is an innovative life science technology company revolutionizing molecular science with its groundbreaking single-molecule imaging platform. This transformational technology utilizes unprecedented super-resolution imaging and deep learning to quantify molecules and their intricate interactions with unparalleled accuracy and reliability.

SMi’s multi-omic platform offers highly scalable throughput and flexibility, allowing the detection of a broad range of molecule types within a single test. This unique approach facilitates faster, better informed decisions that will drive the future of therapeutic and diagnostic development.

Established with a vision to bring its revolutionary platform to every laboratory bench, SMi delivers world-class results without the need for extensive training or specialized knowledge and will transform biomedical research and diagnostics through speed, quality, and versatility.